Highlights on the AIFA Pricing Guidelines
The AIFA Guidelines for the compilation of the dossier supporting the application for the reimbursability and pricing of a medicine have finally been published
21 January 2021
The AIFA Guidelines for the compilation of the dossier supporting the application for the reimbursability and pricing of a medicine have finally been published
Today ICMRA, the international coalition of health regulators from every region of the world, met. Within it are the regulatory agencies
Law No. 178 of 30 December 2020 'State Budget for the Financial Year 2021 and Multiannual Budget for the Year 2021' was published in the Official Journal.
In our country, vaccinovigilance relies on a strong network involving the collaboration of various national and regional institutions (such as the Istituto Superiore di
Pharma Value analysed the Guidelines for the compilation of the dossier supporting the application for the reimbursability and pricing of a medicine and compared them with
On 28 September 2020, the WHO published a document entitled 'WHO guideline on country pharmaceutical pricing policies'. The WHO pricing policies document
On 30 September 2020, we sent to AIFA's dedicated email address our comments on the 'Guidelines for the compilation of the Dossier supporting the
Law 326/2003 established a national fund financed by 5% of pharmaceutical companies' annual expenditure on promotion activities. The 50%
Attention! ART.40 of DECREE-LAW no. 23 of 8 April 2020 'Urgent measures regarding access to credit' repeals ART.17 of the Cura Italia, thus reorganising the
In these times of the COVID-19 emergency we often hear about the '648/96' list and reimbursed drugs for off-label use... but what does this mean? With
